about
Medical genomics: The intricate path from genetic variant identification to clinical interpretationComparison of delivery strategies for pharmacogenetic testing servicesTargeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of CardiologyFrom Metabonomics to Pharmacometabonomics: The Role of Metabolic Profiling in Personalized MedicinePragmatic medicine in solid cancer: a translational alternative to precision medicinePharmacogenetics of heart failure.How can polygenic inheritance be used in population screening for common diseases?Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.Conceptual and terminological confusion around personalised medicine: a coping strategy.V101L of human formyl peptide receptor 1 (FPR1) increases receptor affinity and augments the antagonism mediated by cyclosporins.Personalized Medicine in the U.S. and Germany: Awareness, Acceptance, Use and Preconditions for the Wide Implementation into the Medical Standard.The role of pharmacogenomic biomarkers in predicting and improving drug response: part 2: challenges impeding clinical implementationBiomarkers in atrial fibrillation: a clinical review.Cancer biomarker discovery: current status and future perspectives.Precision medicine, genomics and drug discovery.Driving forces behind the past and future emergence of personalized medicine.Role of pharmacogenomic biomarkers in predicting and improving drug response: part 1: the clinical significance of pharmacogenetic variants.Human genetic variation of CYP450 superfamily: analysis of functional diversity in worldwide populations.A personalized, multiomics approach identifies genes involved in cardiac hypertrophy and heart failure.Big data from electronic health records for early and late translational cardiovascular research: challenges and potential.Personhood and solidarity: what kind of personalized medicine do we want?
P2860
Q26824974-C66983FB-9857-477E-887B-3A93BAD68CCFQ26860925-61D091ED-C43F-4B31-9589-656EC37CD19CQ27024879-FB26F559-0EF4-4E5C-A119-E1F7EBC220B5Q28067029-3BA3820B-45F0-40DD-8AB7-2854A476E265Q28391863-335DBB01-F79B-42A0-B0CA-2CDC719322F1Q33986293-31AF6D22-73AC-4ADD-A08F-972091756A30Q34327946-39EED76D-ADF2-4404-9CB4-6BBDBFBE40A3Q35126801-F410CD11-DB26-4307-A571-F397D3F3B069Q36080996-62F1418B-B307-492E-BBA2-39DA5C0664A1Q36783290-7A4CC24E-5B1F-46AE-9E3E-0E1F1BC587F8Q37063857-9B817D38-8AF5-4942-AA29-0851A8987149Q37419393-B317377B-1FEA-4811-9F1B-30B1D13AA7C4Q38079565-C61540D4-22AF-447D-AAD0-889D0D8CE97EQ38187679-6D76DB6F-1E0A-4877-B8FB-7A1CAE8DD2E5Q38931024-98B931B7-AA0E-448D-8BB9-D152F98AC46EQ39495563-71575ED4-5123-4CAF-A38D-7443D2154B98Q42128113-5A5206E6-2931-45CB-A1AF-C9A62309ACEEQ43555751-594C9AE3-781A-4E5E-B98E-4A2747FFCC99Q50420738-58E0EA89-3B43-4BC9-8F55-BBB54F790878Q52705350-CA923165-CB50-4B08-AEFC-BA704063761FQ57261681-BF0B90E3-3E90-446F-9B37-48E2F3F202F4
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Personalized medicine: hope or hype?
@ast
Personalized medicine: hope or hype?
@en
Personalized medicine: hope or hype?
@en-gb
Personalized medicine: hope or hype?
@nl
type
label
Personalized medicine: hope or hype?
@ast
Personalized medicine: hope or hype?
@en
Personalized medicine: hope or hype?
@en-gb
Personalized medicine: hope or hype?
@nl
prefLabel
Personalized medicine: hope or hype?
@ast
Personalized medicine: hope or hype?
@en
Personalized medicine: hope or hype?
@en-gb
Personalized medicine: hope or hype?
@nl
P2860
P3181
P356
P1476
Personalized medicine: hope or hype?
@en
P2093
Euan A Ashley
Keyan Salari
P2860
P304
P3181
P356
10.1093/EURHEARTJ/EHS112
P407
P577
2012-07-01T00:00:00Z